Arvinas–PhoreMost: TPD drug discovery, 202210– collab multi-target using Siteseeker + PROTAC platforms for targted protein degradation drug discovery

	Period	2022-10-28
	Partner, 1st	Arvinas Inc. (Nasdaq: ARVN)
	Group	Arvinas (Group)
	Partner, 2nd	PhoreMost Ltd.
	Product	Siteseeker® drug target discovery technology

PhoreMost Ltd.. (10/28/22). "Press Release: PhoreMost Enters Multi-target Collaboration with Targeted Protein Degradation Leader Arvinas". Cambridge.

PhoreMost to deploy its SITESEEKER® Targeted Protein Degradation platform to enable drug discovery against multiple therapeutic targets

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-target collaboration with Arvinas, an industry leader in targeted protein degradation (TPD). Under the terms of the agreement, PhoreMost will receive research funding and will be eligible for pre-clinical, clinical, and commercial milestones.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, toward multiple high-value therapeutic targets. The output from SITESEEKER screening campaigns will be used to drive degrader drug discovery in oncology and neurodegeneration using Arvinas’s proprietary PROTAC® Discovery Engine platform.

The SITESEEKER platform is based on PhoreMost’s core proprietary ‘Protein Interference’ (PROTEINi®) technology. PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast shape diversity of proprietary miniprotein libraries. SITESEEKER systematically unmasks new and unanticipated druggable sites across the entire human proteome, directly linking them to useful therapeutic functions.

Dr. Neil Torbett, CEO of PhoreMost, said: “This is another exciting collaboration for our team, and we are delighted to be working together with the leaders in the targeted protein degradation space. For Arvinas to recognise the potential of SITESEEKER to help deliver significant therapeutic breakthroughs is further testament to the progress we have made in developing our platform.”

Dr. Angela Cacace, Senior Vice President of Neuroscience & Platform Biology at Arvinas, said: “Identifying new protein binders is imperative for Arvinas as we expand the capabilities of our PROTAC platform. We are excited to begin this collaboration to leverage PhoreMost's phenotypic screening platform and to make continued progress towards degrading undrugged targets across multiple complex diseases.”

ENDS

Notes to editors:

Dr Neil Torbett, CEO, PhoreMost
For a high-resolution image please contact Zyme Communications

Media enquiries

PhoreMost:

Dr Ben Rutter
Zyme Communications
E-mail: ben.rutter@zymecommunications.com
Tel: +44 (0)7920 770 935

Dr Neil Torbett
CEO, PhoreMost
E-mail: neil.torbett@phoremost.com

About PhoreMost Ltd
www.phoremost.com

PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary 'Protein Interference' technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.

Follow PhoreMost on Twitter @PhoreMostLtd and LinkedIn @PhoreMost

About Arvinas
www.arvinas.com

Arvinas is a clinical-stage biotech company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Follow Arvinas on Twitter @ArvinasInc and LinkedIn @Arvinas